{
    "pmcid": "11530565",
    "qa_pairs": {
        "How do nanobodies targeting the SARS-CoV-2 spike protein have potential therapeutic applications?": [
            "By neutralizing the virus and preventing infection.",
            "By enhancing the immune response to other vaccines.",
            "By serving as a diagnostic tool for COVID-19 detection.",
            "By acting as a delivery vehicle for antiviral drugs."
        ],
        "What are the advantages of using nanobodies to target the SARS-CoV-2 spike protein?": [
            "Their small size allows them to access cryptic epitopes on the spike protein.",
            "They can be easily produced in bacterial systems without post-translational modifications.",
            "They have a longer half-life in the bloodstream compared to conventional antibodies.",
            "They are less likely to elicit an immune response due to their camelid origin."
        ],
        "What is a key challenge in the discovery of antibodies targeting the SARS-CoV-2 spike protein?": [
            "Expression, purification, and stabilization of the spike protein as an antigen.",
            "Finding antibodies that can bind to linear epitopes on the spike protein.",
            "Developing antibodies that can cross the blood-brain barrier.",
            "Ensuring antibodies do not interfere with host cell signaling pathways."
        ],
        "What role do computational tools play in the design of nanobodies against the SARS-CoV-2 spike protein?": [
            "They predict and optimize nanobody interactions with the spike protein.",
            "They simulate the immune response to nanobodies in vivo.",
            "They generate synthetic spike protein sequences for vaccine development.",
            "They design adjuvants to enhance the immunogenicity of nanobodies."
        ],
        "Which antigen format is highlighted for its ability to mimic the native lipid environment of the SARS-CoV-2 spike protein?": [
            "Virus-like particles (VLPs)",
            "Proteoliposomes",
            "Nanodiscs",
            "Recombinant protein fragments"
        ]
    }
}